A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)
- PMID: 35530041
- PMCID: PMC9073076
- DOI: 10.3389/fmed.2022.785785
A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)
Abstract
Background and aim: While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm-designed based on a pathophysiologic and pharmacologic rationale-and including non-steroidal anti-inflammatory drugs, especially relatively selective cyclooxygenase-2 inhibitors and, when needed, corticosteroids, anticoagulants, oxygen therapy and antibiotics-at the very onset of mild COVID-19 symptoms could effectively reduce hospital admissions.
Methods: This fully academic, matched-cohort study evaluated outcomes in 108 consecutive consenting patients with mild COVID-19, managed at home by their family doctors between January 2021 and May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and comorbidities-matched patients on other therapeutic schedules (ClinicalTrials.gov: NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by intention-to-treat.
Results: One (0.9%) patient in the "recommended" cohort and 12 (11.1%) in the "control" cohort were admitted to hospital (P = 0.0136). The proposed algorithm reduced the cumulative length of hospital stays by 85% (from 141 to 19 days) as well as related costs (from €60.316 to €9.058). Only 9.8 patients needed to be treated with the recommended algorithm to prevent one hospitalization event. The rate of resolution of major symptoms was numerically-but not significantly-higher in the "recommended" than in the "control" cohort (97.2 vs. 93.5%, respectively; P = 0.322). Other symptoms lingered in a smaller proportion of patients in the "recommended" than in the "control" cohort (20.4 vs. 63.9%, respectively; P < 0.001), and for a shorter period.
Conclusion: The adoption of the proposed outpatient treatment algorithm during the early, mild phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs.
Keywords: COVID-19; SARS-CoV-2; at home management; hospitalization; outpatients.
Copyright © 2022 Consolaro, Suter, Rubis, Pedroni, Moroni, Pastò, Paganini, Pravettoni, Cantarelli, Perico, Perna, Peracchi, Ruggenenti and Remuzzi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study.EClinicalMedicine. 2021 Jul;37:100941. doi: 10.1016/j.eclinm.2021.100941. Epub 2021 Jun 9. EClinicalMedicine. 2021. PMID: 34127959 Free PMC article.
-
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. Trials. 2021. PMID: 33810796 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Rule to Discharge Patients Safely.Chest. 2021 Oct;160(4):1222-1231. doi: 10.1016/j.chest.2021.05.008. Epub 2021 May 15. Chest. 2021. PMID: 34004154 Free PMC article. Clinical Trial.
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
Cited by
-
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29. J Infect Public Health. 2023. PMID: 36603376 Free PMC article. Review.
-
The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study.Inflammopharmacology. 2024 Dec;32(6):3697-3705. doi: 10.1007/s10787-024-01568-y. Epub 2024 Sep 23. Inflammopharmacology. 2024. PMID: 39312097 Free PMC article.
-
Hypothesis: Efficacy of early treatments with some NSAIDs in COVID-19: Might it also depend on their direct and/or indirect zinc chelating ability?Br J Pharmacol. 2023 Feb;180(3):279-286. doi: 10.1111/bph.15989. Epub 2022 Dec 8. Br J Pharmacol. 2023. PMID: 36482040 Free PMC article.
-
Full-dose NSAIDs at the first sign of respiratory infection? - Authors' reply.Lancet Infect Dis. 2022 Nov;22(11):1534. doi: 10.1016/S1473-3099(22)00646-6. Lancet Infect Dis. 2022. PMID: 36309021 Free PMC article. No abstract available.
-
NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?Inflammopharmacology. 2022 Feb;30(1):343-348. doi: 10.1007/s10787-021-00896-7. Epub 2021 Nov 25. Inflammopharmacology. 2022. PMID: 34822026 Free PMC article.
References
-
- Johns, Hopkins CSSE . COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Available online at: https://www.coronavirus.jhu.edu (accessed September 1, 2021).
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous